Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Gopal, P.; Tasneen, R.; Yee, M.; Lanoix, J.; Sarathy, J.; Rasic, G.; Li, L.; Dartois, V.; Nuermberger, E.; Dick, T.
    In vivo-selected pyrazinoic acid-resistant Mycobacterium tuberculosis strains harbor missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1 (2017), ACS Infect. Dis., 3, 492-501 .
    View publication on PubMedView publication on EuropePMC

Protein Variants

EC Number Protein Variants Comment Organism
4.1.1.11 A128E naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 A128S naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 C17R naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 D116Y naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 E130G naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 F107L naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 H21N naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 H21Q naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 I115V naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 L131P naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 L136P naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 L136R naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 M117I naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 M117V naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 additional information construction of a panD mutant strain, the panD mutant grows as well as the wild-type in infected mice. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. Location of amino acid sequence polymorphisms in PanD of POA-resistant Mycobacterium tuberculosis strains isolated from POA-treated mice Mycobacterium tuberculosis
4.1.1.11 N127K naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 V138A naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis
4.1.1.11 V138M naturally occuring mutation after treatment with pyrazinoic acid Mycobacterium tuberculosis

Organism

EC Number Organism UniProt Comment Textmining
4.1.1.11 Mycobacterium tuberculosis
-
-
-

Synonyms

EC Number Synonyms Comment Organism
4.1.1.11 aspartate decarboxylase
-
 Mycobacterium tuberculosis
4.1.1.11 PanD
-
 Mycobacterium tuberculosis

General Information

EC Number General Information Comment Organism
4.1.1.11 malfunction an in vivo-selected pyrazinoic acid-resistant Mycobacterium tuberculosis strain harbors a missense mutation in the aspartate decarboxylase PanD. Mice infected with wild-type Mycobacterium tuberculosis are treated with pyrazinoic acid (POA), and POA-resistant colonies are confirmed for pyrazinamide (PZA) and POA resistance. Genome sequencing reveals that 82% and 18% of the strains contain missense mutations in panD and clpC1, respectively. POA/PZA resistance-conferring panD mutations are observed in POA-treated mice but not yet among clinical strains isolated from PZA-treated human patients Mycobacterium tuberculosis